BRIDGEWATER — Enzon Pharmaceuticals Inc. said Monday it is selling most of its business to Italian drugmaker sigma-tau Group and will focus on its experimental cancer drugs and technologies. Enzon will get $300 million upfront, along with milestone payments of…

The rest is here:
Enzon Pharmaceuticals sells its specialty-drug unit for $300 million